Abstract
Idiopathic pulmonary fibrosis (IPF) is a rare disease characterized by decline in lung function, dyspnea, and cough. The clinical course of IPF is variable and unpredictable. Early referral to specialists is key to ensure timely and accurate diagnosis. Two antifibrotic drugs (nintedanib and pirfenidone) have been approved for the treatment of IPF.
MeSH terms
-
Clinical Trials as Topic
-
Disease Management
-
Humans
-
Idiopathic Pulmonary Fibrosis / diagnosis*
-
Idiopathic Pulmonary Fibrosis / drug therapy*
-
Indoles / therapeutic use
-
Lung / diagnostic imaging
-
Nurse Practitioners
-
Patient Education as Topic
-
Practice Guidelines as Topic
-
Pyridones / therapeutic use
-
Respiratory System Agents / therapeutic use
-
Self-Management
-
Tomography, X-Ray Computed
Substances
-
Indoles
-
Pyridones
-
Respiratory System Agents
-
pirfenidone
-
nintedanib